Relationship between preoperative serum CA15-3 and CEA levels and clinicopathological parameters in breast cancer

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 4, 2014, Pages 1685-1688

  Moazzezy, Neda ^a   Farahany, Tahereh Zarnoosheh ^a   Oloomi, Mana ^a   Bouzari, Saeid ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Clinicopathological factors; Invasive breast carcinoma; Serum tumor marker

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; MUCIN 1; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD; BREAST TUMOR; FEMALE; HUMAN; IRAN; LUNG CARCINOMA; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; IRAN; MIDDLE AGED; MUCIN-1; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84896985844     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.4.1685     Document Type: Article

References (17)

1. Agha-Hosseini F, Mirzaii-Dizgah I, Rahimi A (2009). Correlation of serum and salivary CA15-3 levels in patients with breast cancer. Med Oral Patol Oral Cir Bucal, 10, 521-4.
2. Atoum M, Nimer N, Abdeldayem S, Nasr H (2012). Relationships among serum CA15-3 tumor marker, TNM staging, and estrogen and progesterone receptor expression in benign and malignant breast lesions. Asian Pac J Cancer Prev, 3, 857-60.
3. Barros AC, Fry W Jr, Nazario AC, Santos MO, Sato MK (1994). Experience with CA 15.3 as a tumor marker in breast cancer. Eur J Surg Oncol, 20, 130-3.
4. Begum M, Karim S, Malik A, et al (2012). CA15-3 (Mucin-1) and physiological characteristics of breast cancer from Lahore, Pakistan. Asian Pac J Cancer Prev, 10, 5257-61.
5. Compton CC, Fielding LP, Burgart LJ, et al (2000). Prognostic factors in colorectal cancer. Arch Pathol Lab Med, 124, 979-94.
6. Duffy MJ (1989). New cancer markers. Ann Clin Biochem, 26, 379-87.
7. Duffy MJ (1999). CA15.3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem, 36, 579-86.
8. Dunnwald LK, Rossing MA, Li1 CI (2007). Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res, 9, 1-10.
9. Keyhani M, Nasizadeh S, Dehghannejad A (2005). Serum CA15-3 measurements in breast cancer patient before and after mastectomy. Arch Iranian Med, 4, 263-6.
10. Martoni A, Zamagni C, Bellanova B, et al (1995). CEA, MCA, CA15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study. Eur J Cancer, 31, 1615-21.
11. Mousavi SM, Mohaghegghi MA, Mousavi-Jerrahi A, Nahvijou A, Seddigh Z (2006). Burden of breast cancer in Iran: a study of the Tehran population based cancer registry. Asian Pac J Cancer Prev, 7, 571-4.
12. Mousavi SM, Gouya MM, Ramazani R, et al (2009). Cancer incidence and mortality in Iran. Ann Oncol, 20, 556-63.
13. Serdarević NJ, Mehanović S (2012). The possible role of tumor antigen CA 15-3, CEA and ferritin in malignant and benign disease. J Health Sci, 2, 138-43.
14. Thriveni K, Krishnamoorthy L, Ramaswamy G (2007). Correlation study of carcino embryonic antigen & cancer antigen 15.3 in pretreated female breast cancer patients. Indian J Clin Biochem, 22, 57-60.
15. Tondini C, Hayes DF, Kufe DW (1989). Circulating tumor markers in breast cancer. Hematol/Onco Clin North Am, 3, 653-74.
16. Vukobrat-Bijedic Z, Husic-Selimovic A, Sofic A, et al (2012). The application of current diagnostic protocols of patients with colon cancer in preparation for therapy. Acta Inform Med, 4, 238-41.
17. Zare M, Rezaee A, Zakiani SH, Zare A (2012). Study of Iranian breast cancer registration via established online system during 2011. IOS Press, 4, 1197-201.